Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Publishing timestamp: 2025-01-26 13:00:01
Summary
Pharmaceutical companies are cautiously optimistic about the Trump administration's approach to healthcare, hoping for reforms that focus on cracking down on pharmacy benefit managers and promoting drug innovation. The industry is particularly eager to see changes to Biden's Inflation Reduction Act. Despite uncertainties, executives are ready to work with Trump, who has signaled a focus on lowering drug costs. Pharmaceutical companies are also hopeful for PBM reform and changes to Medicare's ability to negotiate drug prices. However, concerns remain about potential anti-vaccine views of Robert F. Kennedy Jr. and the impact on vaccination rates. Industry is also pushing for revisions to laws that could impact drug prices and innovation.
Sentiment: MIXED
Tickers: GSK, MRK, NVO, PFE, LLY,
Keywords: novo nordisk a/s, biotech and pharmaceuticals, lilly drn, joe biden, business news, merck & co inc, pfizer inc, donald j. trump, business, gsk plc, biotechnology, health care industry, pharmaceuticals, breaking news: politics, politics,
Source: https://www.cnbc.com/2025/01/26/trump-health-care-plan-likely-good-for-pharmaceutical-companies.html